Ischemic Heart Disease (IHD) Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Class (Angina Pectoris, Myocardial Infarction), By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.23 Billion
CAGR (2026-2031)	4.21%
Fastest Growing Segment	Angina Pectoris
Largest Market	North America
Market Size (2031)	USD 7.98 Billion

Market Overview

The Global Ischemic Heart Disease (IHD) Drugs Market will grow from USD 6.23 Billion in 2025 to USD 7.98 Billion by 2031 at a 4.21% CAGR. Ischemic heart disease drugs encompass pharmaceutical agents designed to manage conditions characterized by restricted blood supply to the heart muscle such as angina pectoris and myocardial infarction. The market growth is fundamentally supported by the rising geriatric population and the increasing prevalence of lifestyle associated comorbidities including obesity and diabetes which necessitate long term pharmacological management. According to the American College of Cardiology, in 2023, ischemic heart disease affected an estimated 240 million people globally. This substantial disease burden underscores the urgent and sustained demand for effective therapeutic interventions across international markets.

A significant challenge potentially impeding market expansion is the expiration of patents for major blockbuster therapies which facilitates the entry of cost effective generic competitors. This patent cliff significantly reduces the revenue streams for originator pharmaceutical companies and forces them to navigate high development costs to introduce novel drugs. Furthermore, stringent regulatory pathways and the immense financial investment required for clinical trials continue to complicate the commercialization process for new market entrants.

Key Market Drivers

The surge in lifestyle-related risk factors is a primary engine for market growth, as modern sedentary behaviors and environmental conditions exacerbate cardiovascular vulnerabilities. Metabolic disorders, particularly obesity, accelerate the progression of atherosclerosis, compelling healthcare providers to prescribe preventative and management pharmacotherapies. According to the American Heart Association, January 2024, in the '2024 Heart Disease and Stroke Statistics Update', the obesity epidemic significantly contributes to cardiovascular risk, with nearly 42% of the U.S. adult population classified as obese. This prevalence directly correlates with the incidence of ischemic events, necessitating sustained drug regimens. Furthermore, the market is driven by environmental contributors to disease burden; according to the World Heart Federation, May 2024, in the 'World Heart Report 2024', ambient air pollution was responsible for approximately 1.9 million deaths specifically from ischemic heart disease in a single year, highlighting the expanding need for therapeutic interventions beyond traditional lifestyle modifications.

Advancements in novel drug therapies and biologics are simultaneously redefining the treatment landscape and expanding the market's revenue potential. The recent clinical success of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular applications marks a significant evolution from traditional symptom management to proactive risk reduction. According to Novo Nordisk, March 2024, in the press release 'Wegovy receives FDA approval for cardiovascular risk reduction', the treatment demonstrated a statistically significant 20% reduction in the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease. This regulatory milestone not only broadens the therapeutic arsenal but also incentivizes pharmaceutical investment in developing multi-modal treatments that address both metabolic and ischemic pathways, thereby capturing a larger share of the patient population.

Download Free Sample Report

Key Market Challenges

Based on the market overview provided, the significant challenge impeding market expansion is the expiration of patents for major blockbuster therapies.

The expiration of patents for major blockbuster therapies constitutes a formidable barrier to the revenue growth of the Global Ischemic Heart Disease (IHD) Drugs Market. When exclusive marketing rights for leading pharmaceutical agents conclude, the market witnesses an immediate influx of bioequivalent generic formulations. These competitors are typically priced significantly lower than their branded counterparts, leading to a rapid erosion of market share for originator companies. Consequently, despite a sustained or increasing volume of prescriptions due to high disease prevalence, the overall monetary value of the market faces downward pressure as sales shift toward these cost-effective alternatives.

This trend is further exacerbated by the intense financial strain on healthcare systems, which aggressively promote the adoption of generic medicines to mitigate soaring healthcare expenditures. The inability to maintain premium pricing models for established drugs forces pharmaceutical developers to rely heavily on new, high-risk innovations to sustain profitability. According to the American Heart Association, in 2024, the total direct and indirect costs related to cardiovascular disease in the United States were projected to triple to approximately $1.8 trillion by 2050. This escalating economic burden underscores the critical market dynamic where payers prioritize reduced spending, thereby amplifying the impact of patent cliffs and restricting the revenue potential for branded ischemic heart disease therapies.

Key Market Trends

The accelerated adoption of PCSK9 inhibitors and targeted biologics is reshaping the market by addressing the critical need for aggressive lipid lowering in high-risk patients unresponsive to standard statin regimens. This trend is characterized by the increasing uptake of small interfering RNA therapies and monoclonal antibodies that offer potent, sustained low-density lipoprotein reduction with infrequent dosing schedules. Consequently, pharmaceutical developers are witnessing substantial revenue growth from these advanced injectables as healthcare systems prioritize secondary prevention tools for ischemic conditions. According to Novartis, October 2024, in the 'Q3 2024 Results', the company's siRNA therapy, Leqvio, recorded sales of $198 million for the quarter, representing a 119% increase compared to the previous year, highlighting the rapid market penetration of these targeted interventions.

Simultaneously, the implementation of precision medicine is driving the development of novel therapeutics designed to mitigate genetically determined cardiovascular risks, specifically elevated Lipoprotein(a). Unlike traditional cholesterol management, this approach utilizes genetic profiling to identify patients with inherited vulnerabilities that remain unaddressed by conventional drugs, fostering a new pipeline of RNA-interference therapies. This shift towards personalized care is evidenced by recent clinical advancements in gene-silencing agents that effectively reduce pathogenic lipoprotein concentrations. According to Silence Therapeutics, November 2024, in the press release 'Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data', the investigational drug zerlasiran demonstrated a time-averaged reduction in Lipoprotein(a) of more than 80% over 36 weeks in patients with established cardiovascular disease, validating the efficacy of these precision modalities.

Segmental Insights

The Angina Pectoris segment represents the fastest-growing category within the Global Ischemic Heart Disease Drugs Market driven by the rising incidence of chronic chest pain among aging populations. This growth is further propelled by the increasing adoption of sedentary lifestyles and poor dietary habits that exacerbate coronary conditions. Moreover, the sector benefits from the consistent approval of therapeutic options by established entities such as the U.S. Food and Drug Administration. These regulatory endorsements facilitate the availability of new medications, thereby addressing the urgent need for effective long-term symptom management and supporting market expansion.

Regional Insights

North America maintains a leading position in the global Ischemic Heart Disease (IHD) drugs market due to the high prevalence of cardiovascular conditions and a well-established healthcare infrastructure. The region benefits from robust reimbursement frameworks that improve patient access to essential medications. Additionally, the presence of major pharmaceutical manufacturers drives continuous product development and clinical research. The United States Food and Drug Administration (US FDA) supports market expansion by streamlining approval processes for new therapeutic options. These combined factors ensure a steady demand for effective treatments across the region.

Recent Developments

• In September 2025, Novartis announced an agreement to acquire Tourmaline Bio for a total value of approximately $1.4 billion to expand its portfolio of medicines for cardiovascular conditions. This acquisition provided the company with access to a lead candidate, an anti-inflammatory monoclonal antibody specifically designed to treat atherosclerotic cardiovascular disease. The strategic transaction highlighted the industry's increasing emphasis on targeting inflammation as a pivotal mechanism in the progression of heart disease. By integrating this late-stage asset, the company aimed to deliver novel therapeutic solutions that address unmet needs in the global market for ischemic heart disease treatments.
• In February 2025, Amgen released breakthrough research data from a Phase 2 clinical trial evaluating its investigational RNA interference therapy, Olpasiran, in patients with elevated Lipoprotein(a) and established atherosclerotic cardiovascular disease. The study results, published in a prominent medical journal, demonstrated that the therapy significantly reduced levels of oxidized phospholipids, which are considered potent drivers of arterial inflammation and plaque rupture. This scientific advancement suggested that the drug could offer a dual benefit by lowering specific lipoproteins and attenuating inflammatory pathways, thereby potentially modifying the underlying disease process in patients suffering from ischemic heart disease.
• In October 2024, AstraZeneca entered into an exclusive license agreement with CSPC Pharmaceutical Group to develop a novel preclinical small molecule aimed at treating dyslipidaemia. The collaboration focused on advancing a Lipoprotein(a) disruptor designed to address residual risk factors that contribute to the progression of ischemic heart disease. Under the commercial terms, the company agreed to pay $100 million upfront, with the potential for an additional $1.92 billion in development and commercial milestones. This strategic partnership aimed to strengthen the company’s cardiovascular pipeline by targeting specific molecular drivers of atherosclerotic disease to improve long-term patient outcomes.
• In March 2024, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for its glucagon-like peptide-1 agonist, Wegovy, to include a new indication for reducing the risk of major adverse cardiovascular events. This regulatory milestone allowed the treatment to be prescribed to adults with established cardiovascular disease and either obesity or overweight. The approval was supported by results from a landmark outcomes trial, which demonstrated that the medication significantly lowered the incidence of non-fatal heart attacks, strokes, and cardiovascular death. This development represented a significant advancement in therapeutic options for mitigating risk factors associated with ischemic heart disease.

Key Market Players

• Bayer AG
• Eli Lilly and Company
• Novartis International AG
• Pfizer, Inc.
• Sanofi S.A.
• Actelion Pharmaceuticals Ltd.
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG

By Disease Class	By Drug Class	By Region
Angina Pectoris Myocardial Infarction	Anti-Dyslipidemic Drugs Calcium Channel Blockers Beta-Blockers ACE Inhibitors ARBs Vasodilators Antithrombotic Agents	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Ischemic Heart Disease (IHD) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Ischemic Heart Disease (IHD) Drugs Market, By Disease Class:

• Angina Pectoris
• Myocardial Infarction

• Ischemic Heart Disease (IHD) Drugs Market, By Drug Class:

• Anti-Dyslipidemic Drugs
• Calcium Channel Blockers
• Beta-Blockers
• ACE Inhibitors
• ARBs
• Vasodilators
• Antithrombotic Agents

• Ischemic Heart Disease (IHD) Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE